BioMedNewsBreaks – Mind Cure Health Inc. (CSE: MCUR) (OTCQB: MCURF) (FRA: 6MH) Names Digital Therapy Visionary as Tech Advisor

August 10, 2021 09:02:16

Mind Cure Health (CSE: MCUR) (OTCQB: MCURF) (FRA: 6MH), a leader in advanced proprietary technology and research for psychedelics, has announced that Dr. Ken Weingardt, CEO of Audacious Digital Health, will be serving as senior clinical technology advisor. Weingardt is a clinical psychologist and has served as senior clinical director at Pear Therapeutics. Specifically,  Weingardt will work with MINDCURE’s iSTRYM, the company’s digital therapeutics technology (“DTx”) platform, through near-term commercial deployment. iSTRYM is on schedule for MVP deployment in the third quarter of 2021, with commercial deployment slated for first quarter 2022. Weingardt , who most recently served as the director of clinical programs at Woebot Health, has two decades of experience focused on technology and behavioral health. iSTRYM is MINDCURE’s proprietary, first-of-its-kind software application that optimizes the healing journey for both patients and clinicians before, during, and after therapy sessions. The platform offers therapists global, evidence-backed treatment protocols, as well as in-session psychedelic-informed tools. In addition, the application features customizable dashboards, integration plans, insights into patient journeys and real-time assessments for personalized client care.

“Adding Ken to our team is a hallmark moment,” said MINDCURE president and CEO Kelsey Ramsden in the press release. “We are in the early days of this fast-growing psychedelics market and are proud that Ken chose to work with MINDCURE. I’m honored and excited to show what we will achieve together. I believe that vision, teamwork, and speed of execution are the keys of every disruptive business that delivers on its strategy and drives results for its customers and its investors.”

To view the full press release, visit

About Mind Cure Health Inc.

MINDCURE is a life sciences company focused on innovating and commercializing new ways to promote healing and improve mental health. The company is developing digital therapeutics technology and researching psychedelic compounds to support access to safe, evidence-based, psychedelic-assisted therapies globally. For more information about the company, please visit

NOTE TO INVESTORS: The latest news and updates relating to MCURF are available in the company’s newsroom at

About BioMedWire

BioMedWire (BMW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) BioMedNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. BMW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information please visit

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published:

BioMedWire (BMW)
San Francisco, California
415.949.5050 Office

BioMedWire is part of the InvestorBrandNetwork